DiseaseLand is a disease-focused public database containing carefully curated data from multiple data types, including single-cell RNA-seq. Leverage QIAGEN’s world-class informatics pipelines, curation and data management to accelerate your cardiovascular, metabolic, immunologic and neurologic disease projects – from biomarker discovery, new target identification and target validation, to drug repositioning and indication discovery.
Used in nearly all stages of drug development (from discovery to preclinical and clinical research), DiseaseLand encompasses multi-omics data, while providing a standardized pipeline for incorporation of data, with controlled vocabularies for associated information.
Utilize public single-cell RNA-seq data
Broad support for genomic data types and thousands of curated and quality-controlled public disease-focused genome datasets
Powerful visualization and analytics to compare and correlate within and across datasets
Internal “Land” next-generation database technology provides very fast access to a large number of genomic datasets
Focus on downstream research
No need to reinvent the wheel! QIAGEN’s bioinformatics team spends thousands of computing, curation and download hours each year to keep up with rapidly growing disease-focused genomics data so you don’t have to. By using our pre-curated datasets and powerful analytics, you can:
Quickly identify high-quality, well-curated, publicly available disease-focused datasets
Find modulation of targets with known compounds and treatments
Organize your datasets for compliance with pharma industry data standards
Save valuable time and resources, while empowering focused research